Insider Selling: Quest Diagnostics (NYSE:DGX) SVP Sells 3,878 Shares of Stock

06 Mar 2026, 22:57 by Danessa Lincoln · The Markets Daily

Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) SVP Michael Prevoznik sold 3,878 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $206.21, for a total value of $799,682.38. Following the sale, the senior vice president owned 37,557 shares of the company’s stock, valued at approximately $7,744,628.97. This trade represents a 9.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Quest Diagnostics Price Performance

Shares of NYSE:DGX traded down $4.61 during trading on Friday, reaching $199.37. The stock had a trading volume of 1,055,721 shares, compared to its average volume of 1,047,341. The business has a fifty day moving average price of $191.19 and a 200-day moving average price of $185.60. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.96 and a current ratio of 1.04. The stock has a market cap of $21.90 billion, a PE ratio of 22.79, a PEG ratio of 2.69 and a beta of 0.66. Quest Diagnostics Incorporated has a 1-year low of $157.20 and a 1-year high of $213.50.

Quest Diagnostics (NYSE:DGX – Get Free Report) last released its earnings results on Tuesday, February 10th. The medical research company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.35 by $0.07. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.57%. The business had revenue of $2.81 billion during the quarter, compared to analyst estimates of $2.75 billion. During the same quarter in the prior year, the firm earned $2.23 earnings per share. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 9.45-9.650 EPS. On average, equities analysts forecast that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current fiscal year.

Quest Diagnostics announced that its Board of Directors has initiated a share repurchase program on Tuesday, February 10th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 4.7% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Quest Diagnostics Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, April 20th. Shareholders of record on Monday, April 6th will be issued a $0.86 dividend. This represents a $3.44 annualized dividend and a yield of 1.7%. The ex-dividend date is Monday, April 6th. This is an increase from Quest Diagnostics’s previous quarterly dividend of $0.80. Quest Diagnostics’s dividend payout ratio (DPR) is currently 36.57%.

Institutional Investors Weigh In On Quest Diagnostics

A number of hedge funds have recently added to or reduced their stakes in DGX. Lebenthal Global Advisors LLC boosted its holdings in Quest Diagnostics by 117.5% in the third quarter. Lebenthal Global Advisors LLC now owns 5,034 shares of the medical research company’s stock valued at $959,000 after purchasing an additional 2,720 shares during the period. Rakuten Investment Management Inc. purchased a new stake in shares of Quest Diagnostics during the third quarter worth approximately $4,713,000. Pacer Advisors Inc. raised its holdings in Quest Diagnostics by 2,531.6% in the third quarter. Pacer Advisors Inc. now owns 450,898 shares of the medical research company’s stock valued at $85,932,000 after acquiring an additional 433,764 shares in the last quarter. TKG Advisors LLC lifted its stake in Quest Diagnostics by 125.1% in the third quarter. TKG Advisors LLC now owns 14,596 shares of the medical research company’s stock worth $2,782,000 after acquiring an additional 8,112 shares during the last quarter. Finally, Cibc World Market Inc. lifted its stake in Quest Diagnostics by 209.6% in the third quarter. Cibc World Market Inc. now owns 7,765 shares of the medical research company’s stock worth $1,480,000 after acquiring an additional 5,257 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DGX has been the subject of a number of analyst reports. Robert W. Baird set a $219.00 price objective on shares of Quest Diagnostics in a report on Wednesday, February 11th. Jefferies Financial Group raised their price target on shares of Quest Diagnostics from $215.00 to $220.00 and gave the stock a “buy” rating in a report on Tuesday, February 10th. Truist Financial lifted their target price on Quest Diagnostics from $205.00 to $220.00 and gave the company a “hold” rating in a research report on Wednesday, February 11th. Weiss Ratings reissued a “buy (b-)” rating on shares of Quest Diagnostics in a research report on Monday, December 29th. Finally, Wall Street Zen cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Sunday, February 22nd. Eight research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $210.29.

View Our Latest Analysis on Quest Diagnostics

About Quest Diagnostics

(Get Free Report)

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.